Immune Cells, if Rendered Insensitive to Transforming Growth Factorbeta, Can Cure Prostate Cancer
Final rept. 2 Jan 2004-1 Jan 2007
NORTHWESTERN UNIV EVANSTON IL
Pagination or Media Count:
The objective of the current proposal is to perform immunotherapy to eradicate prostate cancer and at the same time to avoid the development of autoimmune disease. The proposal contains two tasks. The first task is a combination of IL-2 based tumor-reactive T cell adoptive therapy with the TGF-beta based gene therapy for the treatment of mouse prostate cancer. The second task is A tetracycline inducible TGF-beta based gene therapy. At the time of this report, we have completed Task 1 and three papers have been published. Cancer Research 651761-1769, 2005 Prostate 66235-247, 2006 Molecular Cancer Therapeutics 51733-1743, 2006. Currently, we are in the process of to conduct the final phase of the studies described in Task 2.
- Anatomy and Physiology
- Medicine and Medical Research